Navigation Links
Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015)
Date:5/29/2015

Los Gatos, CA (PRWEB) May 29, 2015

GeneWEAVE, Inc., a clinical diagnostics company addressing multi-drug-resistant organisms (MDROs), announced that initial feasibility data supporting the use of Smarticles™ technology for same-shift bacterial detection and susceptibility testing from positive blood cultures will be presented at asm2015 on May 31, 2015 in New Orleans, LA. The Company’s Smarticles™ technology is a new class of molecular diagnostics that can quickly detect bacteria and assess antibiotic susceptibility directly from clinical samples without the need for sample preparation or organism isolation. The data being presented demonstrates that assays developed with Smarticles™ technology were able to analyze Gram-positive and Gram-negative bacteria for susceptibility to multiple classes of antibiotics as well as determine antibiotic susceptibility of a target pathogen directly from a polymicrobial positive blood culture sample matrix within 4 hours without the need for complex sample preparation.

The data will be presented on Sunday, May 31, 2015 from 10:45AM – 12:00PM in Session 014, Antimicrobial Resistance and Susceptibility Testing: Gram-Positive (Division C). The Company will also be exhibiting at Booth #143 during the meeting at the New Orleans Ernest N. Morial Convention Center and will host a Satellite Symposium at the JW Marriott New Orleans Hotel on June 1 featuring Lance R. Peterson, MD, Director of Microbiology and Infectious Diseases Research at NorthShore University HealthSystem.

“Knowing the most appropriate antibiotic to use for each individual patient’s infection is becoming more important as the levels of antibiotic resistance continue to increase worldwide. Receiving this information quickly is crucial for better patient outcomes - and in sepsis, decreasing time to appropriate treatment is a key component to reducing mortality,” said Steve Tablak, CEO at GeneWEAVE. “The data from this study supports how our Smarticles™ technology can deliver more timely susceptibility results. We are pleased with the growing evidence that supports the application of our transformative Smarticles™ technology for use in an application as important as sepsis.”

The emergence and spread of bacteria that are resistant to currently available antibiotics is a growing worldwide threat recently highlighted by multiple public health agencies including the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC). Antibiotic resistance is further complicating the treatment of infectious diseases where time is of the essence. Easy-to-use diagnostic tests that quickly identify which antibiotics will be effective for a specific infection are needed for better patient outcomes. Obtaining this data via current methods is time-consuming and labor-intensive, taking days to deliver the time-critical antibiotic susceptibility information that healthcare providers need. GeneWEAVE is using Smarticles™ technology to develop direct-from-sample susceptibility tests that will quickly rule-in appropriate antibiotic therapy within hours, so that healthcare providers will know the best treatment to use at the earliest possible moment.

About GeneWEAVE
GeneWEAVE, Inc., based in Los Gatos, Calif., is a privately-held in vitro diagnostics company that is advancing clinical microbiology with diagnostic solutions to aid healthcare providers in the fight against drug-resistant bacteria by enabling impactful surveillance programs, early therapy guidance and successful antibiotic stewardship. The company’s innovative and proprietary Smarticles™ technology harnesses the power of biology to rapidly detect drug resistance and measure susceptibility information without the need for enrichment, culture, or sample preparation. We call this new paradigm, “Sample-In/Susceptibility-Out.”

GeneWEAVE and Smarticles are trademarks of GeneWEAVE, Inc. All rights reserved.

Read the full story at http://www.prweb.com/releases/2015/05/prweb12748227.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. SACHEM Booth #1441 At SEMICON Europa Oct 8-10th, Highlighting Envure System™
2. NYCEDC Announces Winners of Innovate Health Tech, Highlighting Innovation in NYCs Healthcare Sector
3. Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment
4. Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers
5. GeneWEAVE Presents Data for Smarticles™ Assay Targeted Towards Carbapenem-Resistant Enterobacteriaceae (CRE)
6. Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024
7. Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies
8. PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy
9. Cubresa Launches Simultaneous PET/MRI Technology
10. Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players.
11. Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... ... 2017 , ... When James Sherley, was notified earlier this year that his company Asymmetrex ... 2017 by The Silicon Review , he was not surprised as others might be. ... but this recognition by Silicon Valley was particularly meaningful. Our selection by ...
(Date:5/16/2017)... (PRWEB) , ... May 16, ... ... today the general availability of its new ProxiMeta™ Hi-C metagenomic deconvolution service. ... and affordably—without culturing or high-molecular-weight DNA extraction—speeding research insights at lower cost. ...
(Date:5/16/2017)... ... May 16, 2017 , ... ... cancer diagnostics, has released its ClearID Lung Cancer blood test. Leveraging a highly-sensitive ... this new test is designed to quickly and accurately identify tumor-related genetic mutations ...
(Date:5/16/2017)... ... (PRWEB) May 16, 2017 , ... ... (CAOS), long-standing development partners Invibio Biomaterial Solutions, UK, and China’s Double Medical ... help expand knowledge of the implantation of Double Medical’s Direct Lateral Interbody ...
Breaking Biology Technology:
(Date:5/6/2017)... RAM Group , Singaporean based ... in biometric authentication based on a novel  ... to perform biometric authentication. These new sensors are based on ... Ram Group and its partners. This sensor will have ... and security. Ram Group is a next generation ...
(Date:4/18/2017)... Inc., a global expert in SoC-based imaging and computing solutions, has ... features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® ... be showcased during the upcoming Medtec Japan at Tokyo Big Sight ... Las Vegas Convention Center April 24-27. ... Click here for an image of the ...
(Date:4/13/2017)... PUNE, India , April 13, 2017 According ... Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication ... by MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 ... Annual Growth Rate (CAGR) of 17.3%. ... ...
Breaking Biology News(10 mins):